AITP
MCID: THR100
MIFTS: 59

Thrombocytopenic Purpura, Autoimmune (AITP)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thrombocytopenic Purpura, Autoimmune

MalaCards integrated aliases for Thrombocytopenic Purpura, Autoimmune:

Name: Thrombocytopenic Purpura, Autoimmune 57 75 12
Idiopathic Thrombocytopenic Purpura 57 11 19 75 5 14 38 31 33
Autoimmune Thrombocytopenic Purpura 11 19 28 5 14 16 33
Immune Thrombocytopenic Purpura 57 11 71 75 33
Idiopathic Purpura 11 33
Itp 57 19
Thrombocytopenia Due to Platelet Alloimmunization 71
Itp - [idiopathic Thrombocytopenia Purpura] 33
Primary Autoimmune Thrombocytopenic Purpura 33
Purpura, Thrombocytopenic, Idiopathic 43
Thrombocytopenic Purpura Autoimmune 19
Purpura Thrombocytopenic Idiopathic 53
Idiopathic Thrombocytopenia Purpura 33
Frank's Essential Thrombocytopenia 33
Primary Thrombocytopenic Purpura 11
Ideopath Thrombocytopenic Pur 11
Autoimmune Thrombocytopenia 71
Idiopathic Thrombocytopenia 33
Essential Thrombocytopenia 33
Purpura Haemorrhagica 33
Haemorrhagic Purpura 33
Werlhof's Disease 11
Werlhof Disease 33
Aitp 57

Characteristics:


Inheritance:

Autosomal dominant form 57

Classifications:



External Ids:

Disease Ontology 11 DOID:8924
OMIM® 57 188030
ICD9CM 34 287.31
MeSH 43 D016553
NCIt 49 C3446
SNOMED-CT 68 234490009
ICD10 31 D69.3
MedGen 40 C0398650
ICD11 33 364346400
UMLS 71 C0242584 C0272286 C0398650

Summaries for Thrombocytopenic Purpura, Autoimmune

GARD: 19 Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by too few platelets in the blood. This is because platelets are being destroyed by the immune system. Symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation. Rarely, ITP may become a chronic ailment in adults and reappear, even after remission.

MalaCards based summary: Thrombocytopenic Purpura, Autoimmune, also known as idiopathic thrombocytopenic purpura, is related to thrombotic thrombocytopenic purpura and thrombocytosis. An important gene associated with Thrombocytopenic Purpura, Autoimmune is SOCS1 (Suppressor Of Cytokine Signaling 1), and among its related pathways/superpathways are TGF-Beta Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Rituximab and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and skin, and related phenotypes are thrombocytopenia and abnormal bleeding

OMIM®: 57 Autoimmune thrombocytopenic purpura is characterized by a low platelet count, normal bone marrow, and the absence of other causes of thrombocytopenia. It is principally a disorder of increased platelet destruction mediated by autoantibodies to platelet-membrane antigens (George et al., 1994). (188030) (Updated 08-Dec-2022)

Disease Ontology: 11 A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies.

Wikipedia: 75 Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune... more...

Related Diseases for Thrombocytopenic Purpura, Autoimmune

Diseases related to Thrombocytopenic Purpura, Autoimmune via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 986)
# Related Disease Score Top Affiliating Genes
1 thrombotic thrombocytopenic purpura 31.3 SELP GP1BA F8
2 thrombocytosis 31.1 THPO SELP MPL IL11
3 viral infectious disease 31.1 IL18 IFNA2 ICOSLG CCR6
4 exanthem 31.0 IL18 ICOSLG CCR6
5 polycythemia 30.9 THPO MPL ITGB3
6 acquired thrombocytopenia 30.9 THPO MPL ITGB3 ITGA2B IL11 GP1BA
7 qualitative platelet defect 30.8 THPO SELP ITGA2B GP1BA
8 heparin-induced thrombocytopenia 30.7 ITGB3 ITGA2B
9 neutropenia 30.7 THPO MPL IL11 IFNA2
10 crohn's disease 30.7 S100A8 IL18 ICOSLG CCR6
11 hemorrhagic disease 30.7 THPO ITGA2B GP6 GP1BA F8
12 autoimmune polyendocrine syndrome 30.7 LRBA ICOSLG CCR6
13 agammaglobulinemia, x-linked 30.7 LRBA ICOSLG CCR6
14 myelofibrosis 30.7 THPO SELP MPL IFNA2
15 portal vein thrombosis 30.7 THPO MPL F8
16 infective endocarditis 30.7 ITGA2B GP1BA CCR6
17 anemia, autoimmune hemolytic 30.6 SOCS1 RHD LRBA ICOSLG CCR6
18 pulmonary embolism 30.6 GP6 GP1BA F8
19 celiac disease 1 30.6 IL18 ICOSLG HLA-DRB1 CCR6
20 aplastic anemia 30.6 THPO MPL IL11 GP1BA GATA3 CCR6
21 immunoglobulin alpha deficiency 30.6 LRBA ICOSLG CCR6
22 evans' syndrome 30.6 THPO MPL LRBA CCR6
23 splenic sequestration 30.6 THPO SELP MPL ITGA2B
24 thrombosis 30.5 SELP MPL ITGB3 ITGA2B GP6 GP1BA
25 hemolytic anemia 30.5 SOCS1 RHD LRBA IFNA2 CCR6
26 purpura 30.5 THPO SELP MPL ITGB3 ITGA2B HLA-DRB1
27 hematologic cancer 30.5 THPO MPL IL11 ICOSLG CCR6
28 hemoglobinuria 30.5 THPO SELP MPL HLA-DRB1
29 aspergillosis 30.5 IL18 HLA-DRB1 CCR6
30 colitis 30.5 SOCS1 IL18 IL11 ICOSLG HLA-DRB1 GATA3
31 thrombocythemia 1 30.4 THPO MPL
32 lymphadenitis 30.4 IL18 ICOSLG CCR6
33 herpes zoster 30.4 IFNA2 HLA-DRB1 CCR6
34 acquired von willebrand syndrome 30.4 GP6 GP1BA F8
35 myelodysplastic syndrome 30.4 THPO SOCS1 MPL IL11 IFNA2 ICOSLG
36 typhoid fever 30.4 RHD HLA-DRB1 CCR6
37 glanzmann thrombasthenia 1 30.3 SELP ITGB3 ITGA2B GP6 GP1BA F8
38 polyarteritis nodosa 30.3 SELP IFNA2 HLA-DRB1
39 proliferative glomerulonephritis 30.3 SELP ICOSLG CCR6
40 myocardial infarction 30.3 SELP ITGB3 ITGA2B IL18 GP6 GP1BA
41 myelitis 30.3 ITGB3 ITGA2B CCR6
42 bacterial sepsis 30.3 IL18 ICOSLG CCR6
43 coronary thrombosis 30.3 ITGB3 ITGA2B GP6 GP1BA
44 central nervous system vasculitis 30.3 ICOSLG HLA-DRB1 CCR6
45 autoimmune gastritis 30.3 S100A8 ICOSLG CCR6
46 severe covid-19 30.3 IL18 IFNA2 CCR6
47 langerhans cell histiocytosis 30.2 IL11 ICOSLG CCR6
48 childhood type dermatomyositis 30.2 ICOSLG HLA-DRB1 CCR6
49 fungal infectious disease 30.2 IL18 ICOSLG CCR6
50 vogt-koyanagi-harada disease 30.2 ICOSLG HLA-DRB1 CCR6

Graphical network of the top 20 diseases related to Thrombocytopenic Purpura, Autoimmune:



Diseases related to Thrombocytopenic Purpura, Autoimmune

Symptoms & Phenotypes for Thrombocytopenic Purpura, Autoimmune

Human phenotypes related to Thrombocytopenic Purpura, Autoimmune:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thrombocytopenia 30 HP:0001873
2 abnormal bleeding 30 HP:0001892
3 platelet antibody positive 30 HP:0003454

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Heme:
thrombocytopenia
bleeding diathesis

Lab:
platelet antibody

Clinical features from OMIM®:

188030 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 CCR6 DNMT3B F8 GATA3 GP1BA GP6
2 no effect GR00402-S-2 10.2 CCR6 DNMT3B F8 GATA3 GP1BA GP6
3 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 9.43 CCR6 DNMT3B GATA3 GP6 IL18 ITGA2B

MGI Mouse Phenotypes related to Thrombocytopenic Purpura, Autoimmune:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.06 CCR6 DNMT3B F8 GATA3 GP1BA GP6
2 immune system MP:0005387 9.83 CCR6 DNMT3B F8 GATA3 GP6 ICOSLG
3 hematopoietic system MP:0005397 9.55 CCR6 DNMT3B F8 GATA3 GP1BA GP6

Drugs & Therapeutics for Thrombocytopenic Purpura, Autoimmune

Drugs for Thrombocytopenic Purpura, Autoimmune (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rituximab Approved Phase 4 174722-31-7
2
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
3
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5
Clarithromycin Approved Phase 4 81103-11-9 84029
6
Azathioprine Approved Phase 4 446-86-6 2265
7
Alemtuzumab Approved, Investigational Phase 4 216503-57-0
8
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Hydroxychloroquine Approved Phase 4 118-42-3 3652
11
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
12
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
13
Glycyrrhizic acid Approved, Experimental Phase 4 1405-86-3 3495 14982
14
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
15
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
16
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
17
3,4-Dihydroxycinnamic Acid Experimental, Investigational Phase 4 331-39-5, 501-16-6 689043
18
Enoxolone Investigational Phase 4 471-53-4 3230 18526330 10114
19 Antineoplastic Agents, Immunological Phase 4
20 Vitamins Phase 4
21 Calciferol Phase 4
22 Trace Elements Phase 4
23 Vasoconstrictor Agents Phase 4
24 Micronutrients Phase 4
25 Anti-Ulcer Agents Phase 4
26 Antacids Phase 4
27 Cytochrome P-450 Enzyme Inhibitors Phase 4
28 Cytochrome P-450 CYP3A Inhibitors Phase 4
29 Antiprotozoal Agents Phase 4
30 Antiparasitic Agents Phase 4
31 Neuroprotective Agents Phase 4
32 Antimitotic Agents Phase 4
33 Tubulin Modulators Phase 4
34 Antimalarials Phase 4
35 Immunologic Factors Phase 4
36 Anti-Infective Agents Phase 4
37 Autoantibodies Phase 4
38 Antiviral Agents Phase 4
39 Interferon alpha-2 Phase 4
40 interferons Phase 4
41 Interferon-alpha Phase 4
42
Metronidazole Approved Phase 3 443-48-1, 69198-10-3 4173
43
Pantoprazole Approved Phase 3 102625-70-7, 138786-67-1 4679
44
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
45
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
46
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
47
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
48
Dapsone Approved, Investigational Phase 3 80-08-0 2955
49
Oseltamivir Approved Phase 3 204255-11-8, 196618-13-0 65028
50
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7783-07-5, 7782-49-2 533

Interventional clinical trials:

(show top 50) (show all 364)
# Name Status NCT ID Phase Drugs
1 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Unknown status NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
2 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Unknown status NCT04102033 Phase 4 Eltrombopag
3 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Unknown status NCT03771378 Phase 4 rhTPO;eltrombopag
4 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Unknown status NCT04094805 Phase 4 Rocaltrol;Dexamethasone
5 A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients Unknown status NCT04518475 Phase 4 eltrombopag combining rituximab;eltrombopag
6 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
7 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
8 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
9 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
10 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
11 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
12 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab
13 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
14 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
15 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
16 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
17 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
18 Short-course High-dose Prednisone and Dexamethasone in Children With Immune A Multicenter, Randomized Controlled Study of Thrombocytopenia Recruiting NCT05522465 Phase 4 Prednisone;Dexamethasone
19 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
20 Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Recruiting NCT04638829 Phase 4 Avatrombopag Oral Tablet
21 A Multicenter, Randomized Controlled Study of Two Regimens of Intravenous Immune Globulin in the Treatment of Newly Diagnosed Immune Thrombocytopenia in Children Recruiting NCT05520892 Phase 4 intravenous immunoglobulin
22 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
23 Efficacy and Safety of Eltrombopag Combined With Low-dose Rituximab in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to First-line Treatment: a Prospective, Open-label, Nonrandomized, Multicenter Clinical Trial Recruiting NCT04915482 Phase 4 Combined use of eltrombopag with low-dose rituximab;The best available therapy
24 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
25 Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial Recruiting NCT04993885 Phase 4 Avatrombopag
26 A Prospective, Single-center Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood and Adolescent Essential Thrombocythemia Recruiting NCT04226950 Phase 4 Recombinant Interferon Alpha;Pegylated interferon alfa-2b
27 A Prospective, Multicenter, Randomized Controlled Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Adult Essential Thrombocythemia Recruiting NCT05395507 Phase 4 Recombinant Interferon Alpha;Pegylated interferon alfa-2b
28 Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label Trial Not yet recruiting NCT05583838 Phase 4 rhTPO;Eltrombopag
29 Efficacy and Safety of TPO Receptor Agonists as First-line Drugs in the Treatment of Newly Diagnosed Elderly ITP Patients in China-an Open Label Study Not yet recruiting NCT05311930 Phase 4 2.5mg/d Hetrombopag
30 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
31 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
32 Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study Unknown status NCT03177629 Phase 3 treatment : H. pylori eradication
33 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
34 A Multicenter Prospective Randomized Study of Dexamethasone Combined With Decitabine Versus Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03252457 Phase 3 Decitabine;Dexamethasone
35 A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03443570 Phase 3 Rituximab;Bortezomib
36 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
37 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
38 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
39 Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia Unknown status NCT03520049 Phase 3 Oseltamivir;Placebo
40 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
41 A Multicenter Clinical Study of Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia Unknown status NCT03492515 Phase 3 recombinant human thrombopoietin;Platelet Concentrate
42 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
43 A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) Completed NCT01444417 Phase 3 Romiplostim;Placebo
44 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study> Completed NCT00828750 Phase 3 Eltrombopag oral tablets
45 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3 Medical Standard of Care for ITP
46 A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic Purpura Completed NCT00770562 Phase 3 rituximab;Dexamethasone
47 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) -A Multicenter Study in Subjects With Chronic ITP Receiving a Double-Blind, Placebo-Controlled, Short-Term Treatment Followed by an Open-Label, Uncontrolled, Long-Term Treatment- <Phase II/III Study> Completed NCT00540423 Phase 3 SB-497115-GR 12.5mg;SB-497115-GR 25mg;SB-497115-GR 12.5mg matching placebo;SB-497115-GR 50 mg
48 A Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus Conventional Dose Prednisolone for Adults With Untreated Idiopathic Thrombocytopenic Purpura Completed NCT00451594 Phase 3 Dexamethasone;Prednisolone
49 A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00504075 Phase 3
50 Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults Completed NCT00426270 Phase 3 Octagam 10%

Search NIH Clinical Center for Thrombocytopenic Purpura, Autoimmune

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: purpura, thrombocytopenic, idiopathic

Genetic Tests for Thrombocytopenic Purpura, Autoimmune

Genetic tests related to Thrombocytopenic Purpura, Autoimmune:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenic Purpura 28

Anatomical Context for Thrombocytopenic Purpura, Autoimmune

Organs/tissues related to Thrombocytopenic Purpura, Autoimmune:

MalaCards : Bone Marrow, Bone, Skin, T Cells, Spleen, B Cells, Liver

Publications for Thrombocytopenic Purpura, Autoimmune

Articles related to Thrombocytopenic Purpura, Autoimmune:

(show top 50) (show all 7936)
# Title Authors PMID Year
1
Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. 62 57
18654664 2008
2
Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. 62 57
17827395 2008
3
Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. 62 57
15765787 2005
4
Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. 62 57
12472565 2002
5
Immune thrombocytopenic purpura. 62 57
11919310 2002
6
Chronic idiopathic thrombocytopenic purpura. 62 57
7935660 1994
7
Idiopathic thrombocytopenic purpura in two elderly siblings. 62 57
4074042 1985
8
Autoimmune thrombocytopenic purpura. 62 57
2413550 1985
9
Chronic immune thrombocytopenic purpura in monozygotic twins: genetic factors predisposing to ITP. 62 57
6890627 1982
10
Specificity of autoantibodies in autoimmune thrombocytopenia. 62 57
7032627 1982
11
Hereditary autoimmune thrombocytopenic purpura: an immunologic and genetic study. 62 57
7195175 1981
12
Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. 57
9742983 1998
13
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. 57
14850832 1951
14
Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. 53 62
19525300 2010
15
[Expression of T-bet and GATA3 in children with acute idiopathic thrombocytopenic purpura]. 53 62
20113630 2010
16
Thyroid-associated autoimmune coagulation disorders. 53 62
19277469 2010
17
High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. 53 62
19797730 2009
18
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. 53 62
19426124 2009
19
Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura. 53 62
19077159 2009
20
Romiplostim. 53 62
19275274 2009
21
Single nucleotide polymorphism in DNMT3B promoter and the risk for idiopathic thrombocytopenic purpura in Chinese population. 53 62
18437543 2008
22
[Expression of co-stimulatory molecules and role of interleukin 18 in peripheral lymphocytes of patients with idiopathic thrombocytopenic purpura]. 53 62
17605869 2007
23
Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. 53 62
17272505 2007
24
Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. 53 62
17241299 2007
25
Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. 53 62
16915226 2006
26
Novel heterozygous missense mutation in the second leucine rich repeat of GPIbalpha affects GPIb/IX/V expression and results in macrothrombocytopenia in a patient initially misdiagnosed with idiopathic thrombocytopenic purpura. 53 62
16519708 2006
27
[Curative effect of interleukin 11 on chronic idiopathic thrombocytopenic purpura]. 53 62
16584619 2006
28
Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura. 53 62
15870550 2005
29
Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. 53 62
15921398 2005
30
Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin. 53 62
15629743 2004
31
Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. 53 62
15150079 2004
32
[A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura]. 53 62
15355668 2004
33
Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. 53 62
14675413 2004
34
[Interleukin-18 and its related cytokines in plasma of patients with idiopathic thrombocytopenic purpura]. 53 62
14706156 2003
35
Soluble P-selectin, interleukin 6, and thrombopoietin levels in children with acute and chronic idiopathic thrombocytopenic purpura and their relationship with mega-dose methylprednisolone therapy: a pilot study. 53 62
12468916 2002
36
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. 53 62
12411315 2002
37
[Study on the relations between HLA-DRB1 alleles and idiopathic thrombocytopenic purpura in children]. 53 62
12170464 2002
38
Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. 53 62
12209520 2002
39
Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. 53 62
12150725 2002
40
The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. 53 62
11913997 2002
41
[The effects of thrombopoietin and interleukin-11 on bone marrow megakaryocytic progenitors in patients with chronic idiopathic thrombocytopenic purpura in vitro]. 53 62
12528552 2001
42
[The relativity study of thrombopoietin and chronic idiopathic thrombocytopenic purpura]. 53 62
11758228 2001
43
Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. 53 62
11021750 2000
44
[Clinical study on interferon treatment of chronic idiopathic thrombocytopenic purpura]. 53 62
12545843 2000
45
[The sensitivity, specificity and predictive value of PAIgG, reticulated platelets, thrombopoietin levels, and platelet size for the differential diagnosis of thrombocytopenia]. 53 62
10624125 1999
46
Serum thrombopoietin levels in thrombocytopenic and non-thrombocytopenic patients with human immunodeficiency virus (HIV-1) infection. 53 62
10530413 1999
47
Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. 53 62
10525827 1999
48
Usefulness of thrombopoietin in the diagnosis of peripheral thrombocytopenias. 53 62
10406902 1999
49
Systemic causes of excessive uterine bleeding. 53 62
10513767 1999
50
Thrombopoietin, interleukin-6, and P-selectin at diagnosis and during post-steroid recovery period of patients with autoimmune thrombocytopenic purpura. 53 62
9829848 1998

Variations for Thrombocytopenic Purpura, Autoimmune

ClinVar genetic disease variations for Thrombocytopenic Purpura, Autoimmune:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SOCS1 NM_003745.2(SOCS1):c.368C>G (p.Pro123Arg) SNV Likely Pathogenic
977212 rs1244284678 GRCh37: 16:11348968-11348968
GRCh38: 16:11255111-11255111
2 SOCS1 NM_003745.2(SOCS1):c.476_480dup (p.Met161fs) MICROSAT Likely Pathogenic
977214 rs1470306246 GRCh37: 16:11348855-11348856
GRCh38: 16:11254998-11254999
3 SOCS1 NM_003745.2(SOCS1):c.24del (p.Ala9fs) DEL Likely Pathogenic
977213 rs2069587477 GRCh37: 16:11349312-11349312
GRCh38: 16:11255455-11255455

Copy number variations for Thrombocytopenic Purpura, Autoimmune from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21699 1 160500000 165500000 Copy number FCGR2C Idiopathic thrombocytopenic purpura
2 121460 18 43500000 48200000 Copy number SMAD4 Idiopathic thrombocytopenic purpura
3 46119 10 77700000 82000000 Copy number BMPR1A Idiopathic thrombocytopenic purpura

Expression for Thrombocytopenic Purpura, Autoimmune

Search GEO for disease gene expression data for Thrombocytopenic Purpura, Autoimmune.

Pathways for Thrombocytopenic Purpura, Autoimmune

GO Terms for Thrombocytopenic Purpura, Autoimmune

Cellular components related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.28 SELP RHD ITGB3 HLA-DRB1 GP6 GP1BA
2 plasma membrane GO:0005887 10.28 SELP RHD ITGB3 HLA-DRB1 GP6 GP1BA
3 cell surface GO:0009986 10 CCR6 GP1BA GP6 HLA-DRB1 ITGA2B ITGB3
4 external side of plasma membrane GO:0009897 9.5 SELP MPL ITGB3 ITGA2B ICOSLG HLA-DRB1
5 platelet alpha granule membrane GO:0031092 9.43 SELP ITGB3 ITGA2B

Biological processes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cytokine production GO:0001817 9.91 SOCS1 ICOSLG GATA3
2 platelet aggregation GO:0070527 9.88 MPL ITGB3 GP1BA
3 blood coagulation, intrinsic pathway GO:0007597 9.76 GP1BA F8
4 thrombopoietin-mediated signaling pathway GO:0038163 9.67 MPL THPO
5 lymphocyte migration GO:0072676 9.62 CCR6 GATA3
6 regulation of T-helper cell differentiation GO:0045622 9.56 HLA-DRB1 GATA3
7 blood coagulation GO:0007596 9.5 ITGB3 GP6 GP1BA F8
8 hemostasis GO:0007599 9.33 GP6 GP1BA F8
9 humoral immune response GO:0006959 9.23 IFNA2 HLA-DRB1 GATA3 CCR6

Sources for Thrombocytopenic Purpura, Autoimmune

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....